Trustbridge Partners and Jiangsu Simcere Pharmaceutical, one of China’s largest drug companies, have led a US$30 million series B funding round in Veritas Genetics, a Boston and Hangzhou-based start-up that offers whole genome sequencing to consumers for US$999.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
